Correlation Engine 2.0
Clear Search sequence regions


  • c MYC (1)
  • cancer (3)
  • hepatocellular carcinoma (17)
  • hepatoma (3)
  • liver cancer (1)
  • livers (2)
  • MCT1 (3)
  • mice (1)
  • micrornas (7)
  • MYC (2)
  • patients (1)
  • therapies (1)
  • tumour (5)
  • tumour suppressor (7)
  • Sizes of these terms reflect their relevance to your search.

    Hepatocellular carcinoma (HCC) is a cancer with multiple aetiologies and widespread prevalence. Largely refractory to current treatments, HCC is the fourth leading cause of cancer-related deaths worldwide. MicroRNAs (miRNAs) are important regulators in HCCs. We aimed to identify tumour suppressor miRNAs during tumour regression in a conditional c-MYC-driven mouse model (LT2/MYC) of HCC, and to evaluate their therapeutic potential for HCC treatment. We performed miRNA expression profiling of developed and regressing LT2/MYC tumours and in-depth in vitro gain- and loss-of-function analyses. The effect of adeno-associated virus (AAV) vector-mediated miR-342-3p treatment was evaluated in 3 HCC mouse models. We identified miR-342-3p as a tumour suppressor miRNA in HCC, with increased expression in regressing tumours. Forced miR-342-3p expression in hepatoma cells showed significantly decreased cell proliferation, migration, and colony formation. In vivo administration of AAV-miR-342-3p led to significant attenuation of tumour development and increased overall survival. We identified monocarboxylic acid transporter 1 (MCT1) as a bona fide target of miR-342-3p in HCC. We show that the tumour suppressor role of miR-342-3p is executed partly by modulating the lactate transport function of MCT1. Importantly, we find miR-342-3p downregulated in tumours from patients with HCC compared with matched non-tumour tissues, inversely correlating with MCT1 expression. We observed similar findings in TCGA-LIHC data. In our study, we identified and validated miR-342-3p as a tumour suppressor miRNA in HCC. We demonstrated its therapeutic efficacy in significantly attenuating tumour development, and prolonging survival, in different HCC mouse models. Identification of miR-342-3p as an effective tumour suppressor opens a therapeutic avenue for miRNA-mediated attenuation of HCC development. Hepatocellular carcinoma (HCC), the most common type of liver cancer, affects diverse populations and has a global impact, being the fourth leading cause of cancer deaths worldwide. There are currently no systemic therapies for HCC that can significantly prolong long-term survival. Thus, novel effective treatment options are urgently required. To understand the molecular basis of tumour regression, we compared tumours and regressing liver tumours in mice. We show that a small non-coding miRNA, miR-342-3p, is a tumour suppressor in HCC. Expression of miR-342-3p is low in tumours and high in regressing tumours. When miR-342-3p is delivered to mouse livers with HCC, it can significantly slow down liver tumour development and improve survival. Our study highlights the promising therapeutic potential of miR-342-3p intervention in HCC. Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

    Citation

    Ronja-Melinda Komoll, Qingluan Hu, Olaniyi Olarewaju, Lena von Döhlen, Qinggong Yuan, Yu Xie, Hsin-Chieh Tsay, Joel Daon, Renyi Qin, Michael P Manns, Amar Deep Sharma, Andrei Goga, Michael Ott, Asha Balakrishnan. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. Journal of hepatology. 2021 Jan;74(1):122-134


    PMID: 32738449

    View Full Text